The European Medicines Agency (EMA) has recommended extending use of Comirnaty to adolescents aged 12 to 15 years. Currently, the use of this vaccine from the Pfizer / BioNTech consortium has been approved from 16 years. Following the EMA's recommendation, a decision on the change will be issued by the European Commission and such a decision will automatically be valid in all EU Member States.
For more see this link.
